Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All casirivimab/imdevimab..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchCasirivimab/imdevimabCasirivimab/i.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Hospitalization -91% Improvement Relative Risk ER visit -91% Mabs for COVID-19  Stimes et al.  EARLY TREATMENT Is early treatment with mAbs beneficial for COVID-19? Retrospective 262 patients in the USA (December 2020 - May 2022) Higher hospitalization (p=0.5) and progression (p=0.38), not sig. c19early.org Stimes et al., Open Forum Infectious D.., Nov 2023 Favors mAbs Favors control

COVID-19 Monoclonal Antibody Use at a Stand Alone Children’s Hospital

Stimes et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofad500.615
Nov 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
17th treatment shown to reduce risk in March 2021
 
*, now known with p = 0.0000087 from 27 studies, recognized in 42 countries. Efficacy is variant dependent.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
Retrospective 262 pediatric patients referred for COVID-19 monoclonal antibody treatment, 134 treated (74% receiving casirivimab/imdevimab), showing higher ER visits and hospitalization with treatment, without statistical significance. Authors do not provide results for specific treatments.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for many omicron variants Haars, Liu, Pochtovyi, Sheward, Tatham, VanBlargan.
risk of hospitalization, 91.0% higher, RR 1.91, p = 0.50, treatment 6 of 134 (4.5%), control 3 of 128 (2.3%).
ER visit, 91.0% higher, RR 1.91, p = 0.38, treatment 8 of 134 (6.0%), control 4 of 128 (3.1%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Stimes et al., 27 Nov 2023, USA, peer-reviewed, 6 authors, study period 1 December, 2020 - 5 May, 2022.
This PaperCasirivimab/i..All
PharmD, MPA, BCIDP Grant T Stimes, PharmD, BCIDP Brittany Rodriguez, PharmD Amanda Gillispie, MSN, MHA, RN, CPHON Tanya J Hilliard, MD, MSc Flor M Munoz, MD Lisa Forbes Satter
50 vs WA1). Evaluation of CH.1.1 and XBF by introducing variant-defining mutations into the replicon showed no change in in vitro susceptibility (< 1.8-fold change). Phenotyping of clinical isolates of BF.7, BQ.1, XBB.1.5, and CH.1.1 indicated no loss of RDV or ODV in vitro antiviral activity (< 1.3-fold change).
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit